Kiora Pharmaceuticals, Inc. Share Price & Technical Analysis
KPRX · $2.70 (+5.47%)
Healthcare / Biotechnology
$2.70
+5.47%
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also devel…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
17% return in May, -21% avg return in past 3 year May month.
36% return in 2026, -64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 20% | -12% | -10% | 21% | 17% | – | – | – | – | – | – | – | 36% |
| 25 | 21% | -20% | -6% | 7% | -9% | -3% | -7% | 8% | 0% | -18% | -9% | 0% | -37% |
| 24 | 4% | -12% | 5% | -29% | -4% | -7% | 15% | -18% | 0% | -3% | -6% | 0% | -53% |
| 23 | 2% | 22% | -25% | 33% | -50% | -67% | -7% | -17% | 16% | -2% | -11% | 4% | -102% |
| 22 | -45% | -19% | 0% | -15% | -15% | 10% | -67% | 28% | -19% | 6% | -46% | -4% | -186% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.73M
P/E ratio
—
52W high
$4.18
52W low
$1.76
Volume
74,224
Beta
-0.47
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Kiora Pharmaceuticals, Inc. share price today?
- Kiora Pharmaceuticals, Inc. (KPRX) last traded around $2.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KPRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KPRX. Download the app for real-time alerts.
- How can I analyze Kiora Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.